Drug intelligence / Profile preview

LY3873862

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY3873862 is an orally administered small molecule drug candidate developed by Eli Lilly. It acts as a selective inhibitor of SARM1 (sterile alpha and TIR motif containing 1 protein), a key enzyme involved in axonal degeneration and neuronal cell death. By inhibiting SARM1, LY3873862 aims to protect neurons from degeneration, making it a potential neuroprotective therapy for conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The drug is currently in phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers.

Targets

SARM1

Beyond the preview

Go deeper on LY3873862.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3873862.

Explore the full profile